A2M China label infant formula Source: Synlait Milk
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Synlait Milk (SM1) secures approval from China’s State Administration for Market Regulation to re-register the a2 Milk Company’s (A2M) Chinese-label infant milk formula (IMF)
  • The IMF product is approved for three stages and is formulated in line with China’s national GB standards
  • SM1 claims the re-registration is “pivotal” for its ongoing manufacturing and supply agreement with the a2 Milk Company, which will export its IMF product into Chinese markets until September 2027
  • Production at the Dunsandel facility is expected to begin this month, ahead of commercialisation 1H 2024
  • SM1 shares were trading at $1.65, while A2M was at $5.71 at 10:45 am AEST

Synlait Milk (SM1) has received approval from China’s State Administration for Market Regulation (SAMR) to re-register the a2 Milk company’s (A2M) Chinese-label infant milk formula (IMF).

The IMF product has been approved for three stages, and has been formulated in line with China’s national GB standards at Synlait’s Dunsandel facility.

The approval will allow the company to manufacture and export the IMF for Chinese markets until September 2027.

SM1 claims the re-registration is “pivotal” for its ongoing manufacturing and supply agreement with the a2 Milk company.

“We are thrilled to have achieved this significant milestone, which is pivotal to the long-term success of our Advanced Nutrition business,” Synlait CEO Grant Watson said.

“Synlait and The a2 Milk Company have a long-standing and complementary partnership, and we look forward to continuing to support their China growth ambitions.”

Production at the Dunsandel facility is expected to begin this month ahead of commercialisation in the first half of 2024.

The a2 Milk Company Managing Director and CEO David Bortolussi said the approval provided the company with continued access to China’s substantial milk formula market, which remains a “key” focus of the company’s refreshed growth strategy.

SM1 shares were up 10.7 per cent, trading at $1.65, while A2M shares were up 6.93 per cent to $5.71 at 10:45 am AEST.

SM1 by the numbers
More From The Market Online
Market Close Graphic

Market Close: Oil hits 4-year lows on trundling December day; DRO dives | Dec 17

Good afternoon, and welcome to Wednesday’s Market Close.
Market concept

ASX Market Close: October back again as DRO, EOS, 4DX pop; otherwise mid day

If you wanted to feel like you were re-living the festivity season for the XJO that was October, look no further than today’s
The Market Online Video

Inside Racura Oncology: Strategy, clinical milestones, and the year ahead

It's been a huge year for Racura Oncology, and CY26 only promises to get bigger as…
The Market Online Video

How EVR’s 99% antimony concentrate sets up Los Lirios drilling

EVR chief executive Mike Brown joins The Market Link to talk all the latest developments unfolding…